Halozyme Therapeutics (HALO) Amortization - Intangibles: 2022-2025
Historic Amortization - Intangibles for Halozyme Therapeutics (HALO) over the last 4 years, with Sep 2025 value amounting to $17.8 million.
- Halozyme Therapeutics' Amortization - Intangibles changed negligibly% to $17.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $71.0 million, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $71.0 million for FY2024, which is 3.69% down from last year.
- As of Q3 2025, Halozyme Therapeutics' Amortization - Intangibles stood at $17.8 million, which was down 0.00% from $17.8 million recorded in Q2 2025.
- In the past 5 years, Halozyme Therapeutics' Amortization - Intangibles registered a high of $27.2 million during Q3 2022, and its lowest value of $4.6 million during Q4 2022.
- In the last 3 years, Halozyme Therapeutics' Amortization - Intangibles had a median value of $17.8 million in 2025 and averaged $18.0 million.
- The largest annual percentage gain for Halozyme Therapeutics' Amortization - Intangibles in the last 5 years was 290.20% (2023), contrasted with its biggest fall of 25.20% (2023).
- Quarterly analysis of 4 years shows Halozyme Therapeutics' Amortization - Intangibles stood at $4.6 million in 2022, then surged by 290.20% to $17.8 million in 2023, then remained steady at $17.8 million in 2024, then remained steady at $17.8 million in 2025.
- Its last three reported values are $17.8 million in Q3 2025, $17.8 million for Q2 2025, and $17.8 million during Q1 2025.